Preliminary Evaluation of Zanubrutinib-Containing Regimens in DLBCL and the Cerebrospinal Fluid Distribution of Zanubrutinib: A 13-Case Series

Zanubrutinib is a second-generation Bruton’s tyrosine kinase inhibitor. Its safety and effectiveness in central nervous system (CNS) lymphoma along with its distribution in the brain and ability to cross the blood–brain barrier (BBB) remain unknown. This retrospective case series involved patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yan, Li, Yanan, Zhuang, Zhe, Wang, Wei, Wei, Chong, Zhao, Danqing, Zhou, Daobin, Zhang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739956/
https://www.ncbi.nlm.nih.gov/pubmed/35004280
http://dx.doi.org/10.3389/fonc.2021.760405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739956/
https://www.ncbi.nlm.nih.gov/pubmed/35004280
http://dx.doi.org/10.3389/fonc.2021.760405

Ejemplares similares